Litigation Details for Pfizer Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2018)
✉ Email this page to a colleague
Pfizer Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-10-03 |
| Court | District Court, D. Delaware | Date Terminated | 2019-04-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | PFIZER INC. | ||
| Patents | 6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; 9,937,181; RE41,783 | ||
| Attorneys | Linnea P. Cipriano | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pfizer Inc. v. Sun Pharmaceutical Industries Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in Pfizer Inc. v. Sun Pharmaceutical Industries Limited
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Pfizer Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-03 | 1 | four additional patents for Xeljanz XR that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December… infringement of United States Patent No. 9,937,181 (the “’181 patent”). 2. This action…2022). The ’181 Patent 23. On April 10, 2018, the USPTO issued the ’181 patent, titled “Tofacitinib….” The ’181 patent is duly and legally assigned to Pfizer Inc. A copy of the ’181 patent is attached …’181 patent. 30. Sun’s Detailed Statement alleges that all claims of the ’181 patent are | External link to document | |
| 2018-10-03 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,937,181 B2. (crb) (Entered:…2018 11 April 2019 1:18-cv-01529 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
